Ocugen Inc. (OCGN) News
Filter OCGN News Items
OCGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCGN News Highlights
- For OCGN, its 30 day story count is now at 7.
- Over the past 20 days, the trend for OCGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about OCGN are GENE, LCA and NOV.
Latest OCGN News From Around the Web
Below are the latest news stories about OCUGEN INC that investors may wish to consider to help them evaluate OCGN as an investment opportunity.
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceMALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking |
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call TranscriptOcugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […] |
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt DiseaseMALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the ret |
Q3 2023 Ocugen Inc Earnings CallQ3 2023 Ocugen Inc Earnings Call |
Ocugen (OCGN) Q3 2023 Earnings Call TranscriptJoining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's chairman, CEO, and co-founder, who will provide a business update and an overview of our clinical and operational progress. Michael Breininger, our corporate controller is also on the call to provide a financial update for the quarter ended September 30, 2023. |
Ocugen Inc (OCGN) Reports Q3 2023 Financial Results and Business UpdatesOcugen Advances Clinical Programs and Maintains Strong Cash Position Amidst Operating Expense Management |
Ocugen Provides Business Update with Third Quarter 2023 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a pediatric patient OCU400 Phase 1/2 study results suggest stabilization or improvement of Best-Corrected Visual Acuity (BCVA) or Multi-Luminance Mobility Testing (MLMT) or Low-Luminance Visual Acuity (LLVA) in treated eyes of 83% (10/12) subjectsStabilization or i |
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development SummitMALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston |
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial ResultsMALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023. Ocugen will issue a pre-market earnings announcement on |
Why Is Archer Aviation (ACHR) Stock Moving Today?Archer Aviation stock is on a wild ride Tuesday morning after a short report targeting one of its rivals sent ACHR shares down this morning. |